---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Aldosterone synthase inhibitors"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Aldosterone synthase inhibitors. Topics: Class: a new mechanism developed to treat hypertension; Baxdrostat (BAXFENDY): the first approved aldosterone synthase inhibitor; Baxdrostat: BaxHTN, uncontrolled or resistant hypertension; Baxdrostat: Bax24, resistant hypertension; 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/aldosterone-synthase-inhibitors"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Aldosterone synthase inhibitors

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Aldosterone Synthase Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

### Class: a new mechanism developed to treat hypertension

> “A new class of medications called aldosterone synthase inhibitors (ASI), which decrease production of aldosterone, has been developed to treat hypertension.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Inhibition of aldosterone synthase by baxdrostat decreases plasma aldosterone concentrations, thereby reducing blood pressure.”
> “Baxdrostat has a higher potency and selectivity for aldosterone synthase compared to the closely related enzyme 11β-hydroxylase (final enzyme in cortisol synthesis).”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### Baxdrostat (BAXFENDY): the first approved aldosterone synthase inhibitor

> “BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”
> “The recommended dosage of BAXFENDY is 2 mg orally once daily.”
> “Initial U.S. Approval: 2026”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “If approved, Baxfendy will be the first and only aldosterone synthase inhibitor (ASI) in the EU, directly targeting aldosterone to address a key biological driver of elevated blood pressure.”

Source: [AstraZeneca press release, Baxfendy EU CHMP opinion (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/baxfendy-recommended-for-approval-in-the-eu.html)

<a id="topic-2.2.2.1.5-3"></a>

### Baxdrostat: BaxHTN, uncontrolled or resistant hypertension

> “This multinational, randomized, double-blind, placebo-controlled phase 3 trial recruited participants with seated office systolic blood pressure (seated-SBP) ≥140 mmHg and <170 mmHg, despite stable treatment with 2 (uncontrolled hypertension) or ≥3 (resistant hypertension) antihypertensive medications, including a diuretic.”
> “At week 12, change from baseline in least-squares mean seated-SBP for baxdrostat 1mg was –14.5 mmHg (95% confidence interval [CI], –16.5 to –12.5); baxdrostat 2mg, –15.7 mmHg (–17.6 to –13.7); versus placebo, –5.8 mmHg (–7.9 to –3.8).”

Source: [Flack et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618089/)

<a id="topic-2.2.2.1.5-4"></a>

### Baxdrostat: Bax24, resistant hypertension

> “Following a 2-week placebo run-in period, patients with 24 h ambulatory SBP ≥130 mm Hg were randomly assigned (1:1) to receive 2 mg baxdrostat or placebo orally once daily for 12 weeks, in addition to background therapy (stratified by baseline ambulatory SBP <140 mm Hg or ≥140 mm Hg).”
> “Baxdrostat significantly reduced 24 h ambulatory SBP versus placebo in patients with resistant hypertension, providing further evidence of the potential of aldosterone synthase inhibition for treatment of hard-to-control hypertension.”

Source: [Azizi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41794437/)

<a id="topic-2.2.2.1.5-5"></a>

### Baxdrostat: chronic kidney disease with uncontrolled hypertension

> “Baxdrostat showed placebo-corrected reduction in systolic BP of –8.1 (95% confidence interval, –13.4 to –2.8) mm Hg, P = 0.003.”

Source: [Dwyer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12889919/)

<a id="topic-2.2.2.1.5-6"></a>

### Lorundrostat: investigational aldosterone synthase inhibitor under FDA review

> “Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone.”
> “Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.”
> “Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.2.2.1.5-7"></a>

### Vicadrostat: investigational, without a hypertension trial in its phase 3 set

> “In partnership with the University of Oxford, EASi-KIDNEY looked at whether vicadrostat (BI 690517), an investigational compound, in combination with empagliflozin, which has been on the market since 2014, versus empagliflozin alone, could slow kidney disease progression and reduce cardiovascular risk in people with chronic kidney disease.”
> “After a comprehensive benefit-risk assessment of the available data from the study, the company concluded that accumulating trial data did not support a meaningful expectation of clinical benefit in the EASi-KIDNEY chronic kidney disease population for the primary composite endpoint.”
> “EASi program contains three ongoing phase III studies: EASi-HF Preserved, EASi-HF-Reduced and EASi-PROTKT”

Source: [Boehringer Ingelheim press release, EASi-KIDNEY update (2026)](https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial)

<a id="topic-2.2.2.1.5-8"></a>

### Class effect on blood pressure and electrolytes across randomized trials

> “ASI reduced systolic blood pressure (SBP) (MD: –6.7 mm Hg; CrI: −8.78, −4.59; τ2 3.24), diastolic blood pressure (MD: -2.09 mm Hg; CrI: −3.68, −0.44; τ2 1.44), and hypertensive urgency (OR: 0.36; CrI: 0.13, 0.90; τ2 0.07) compared with placebo.”
> “Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.”

Source: [Queiroga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13100762/)

<a id="topic-2.2.2.1.5-9"></a>

### Long-term follow-up available for the class

> “The longest available follow-up data for lorundrostat is 12 weeks”
> “Despite effective blood pressure lowering, questions remain about the long-term effects of ASIs, as well as their impact on patient-important outcomes and their efficacy and safety in key subgroups (e.g., advanced chronic kidney disease).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

Additional sources: [Rasmussen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12281267/); [Judge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12209857/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
